BMY · Bristol-Myers Squibb Co. · Stock research

Current Thesis

The narrative leg on offer is a legacy-pharma re-rating: a company priced for loss-of-exclusivity decay printing a quarter that argues the trough is shallower than modelled. On 2026-07-30 Bristol-Myers reported Q2 2026 adjusted EPS of $2.04 against a $1.59 consensus and revenue of $12.973B against $11.745B, then raised FY2026 sales guidance to $49.000–50.000B from $46.000–47.500B (consensus $47.472B) and FY2026 adjusted EPS to $6.75–7.00 from $6.05–6.35 (consensus $6.34).

A second leg — an AstraZeneca combination reported by Benzinga on 2026-08-02 at a $400B scale — was contradicted by a Reuters exclusive on 2026-08-05 quoting "no discussions" and "never was a deal to be done." The stock nonetheless closed 2026-08-07 at $64.72, 1.8% under the $65.89 52-week high. What is left standing is the fundamental leg, and it is running with RSI(14) at 71.9 into a regulatory decision dated 2026-08-17.

Bullish and bearish views on Bristol-Myers Squibb Co.

The model's bull view on Bristol-Myers Squibb Co. (BMY), in brief: The raise is large and it is guidance, not a beat. The bear view: The entry is extended. RSI(14) 71.9 at the 2026-08-07 close of $64.72, 1.8% from the 52-week high, +16.5% over three months. Buying the second week of a gap-driven advance is a different proposition from buying the print. Two of the eight post-print sell-side anchors sit at or… Both cases follow in full.

Bull Case

• The raise is large and it is guidance, not a beat. Both FY2026 ranges moved on 2026-07-30, with the new sales floor ($49.000B) above the prior ceiling ($47.500B) and above the $47.472B consensus. Guidance ranges that reset entirely above the old range are a different signal from a single-quarter revenue beat.
• Growth portfolio scale. On the Q2 2026 call (2026-07-30) management put growth-portfolio revenue at $7.6B, +14% YoY, approaching 60% of total revenue — the mix shift the LOE-discount thesis says cannot happen fast enough.
• Named product momentum, Q2 2026: Camzyos $416M (+59%), Cobenfy $63M (+81%), Qvantig $261M and described as annualising above $1B, Breyanzi +41%, Reblozyl +29%.
• Eliquis outlook raised to 20–25% FY2026 growth from 10–15% (Q2 2026 call, 2026-07-30) — notable because Eliquis sat in the first CMS Medicare negotiation cohort with negotiated prices effective 2026-01-01.
• Sell-side revisions moved one direction after the print. On 2026-07-31: JPMorgan Overweight PT to $73, Guggenheim Buy PT to $75, Wells Fargo Equal-Weight PT to $65, RBC Sector Perform PT to $64, Cantor Neutral PT to $59, Truist reiterated Buy. Citigroup raised to $70 on 2026-08-03; Argus upgraded to Buy with a $75 target on 2026-08-05.
• A dated pipeline print sits inside the window. The FDA accepted the iberdomide NDA on 2026-02-17 with Priority Review and Breakthrough Therapy Designation, target action 2026-08-17, based on a planned MRD-negativity analysis from the Phase 3 EXCALIBER-RRMM study of iberdomide plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma.

Bear Case

• The entry is extended. RSI(14) 71.9 at the 2026-08-07 close of $64.72, 1.8% from the 52-week high, +16.5% over three months. Buying the second week of a gap-driven advance is a different proposition from buying the print.
• Two of the eight post-print sell-side anchors sit at or under spot. RBC $64 and Cantor $59 (both 2026-07-31) imply no upside from the last close; Wells Fargo $65 is fractionally above. The bull anchors cluster at $73–75.
• Reported revenue growth was +5.7% YoY despite the roughly 10% beat versus consensus — the surprise measures the bar, and the bar was low.
• The merger leg was denied. Reuters, 2026-08-05. Jim Cramer characterised the report as a "fake out" on 2026-08-03. Any premium priced on 2026-08-03 rests on no confirmed transaction, no filing and no company statement.
• Patent arithmetic is unresolved past FY2026. Coverage on 2026-08-03 framed the merger speculation explicitly around patent expirations and deal economics. One raised Eliquis year does not settle 2027–2028.
• The 2026-08-17 decision is binary. A complete response letter or a delay removes the only dated pipeline event inside the window.

Setup & Price Structure

Last completed daily close $64.72 (2026-08-07); 52-week high $65.89; distance from high −1.8%; three-month return +16.5%; RSI(14) 71.9.

Two events are stacked in the recent tape: the 2026-07-30 earnings reaction and the 2026-08-03 merger-headline surge. The observable that carries weight is what happened after the 2026-08-05 Reuters denial — price did not round-trip through those levels, and two sessions later sat within 2% of the 52-week high. Holding a rumour-driven advance after the rumour is retracted is evidence the bid is not purely event-driven.

Life-cycle: ACCELERATING. The dating is dense and recent — beat and raise 2026-07-30, six price-target revisions 2026-07-31, merger report 2026-08-02, surge 2026-08-03, upgrade 2026-08-05. New attention, expanding coverage, fresh headlines. The M&A sub-leg is separately DEAD as of the 2026-08-05 denial; the ACCELERATING label rests only on the earnings re-rating. It flips toward MATURING when price-target revisions stop arriving and price chops beneath the high for several weeks without a new datapoint.

Crowding and positioning observables, stated as observables: RSI above the conventional 70 threshold; price above two of the eight targets published since 2026-07-31; no earnings inside the window, since the print already happened on 2026-07-30 and the next is roughly late October; no Form 4 activity in the recent-filings window reviewed for this note; the near-term binary is regulatory, not financial. Retail-sentiment coverage clustered on 2026-08-03 around the merger headline ("Why Is Bristol-Myers Squibb Stock Surging Monday?"), which is the kind of attention spike that arrives with the last buyers.

Catalyst Calendar (next 30 days)

• 2026-08-17 — FDA target action date, iberdomide + daratumumab/dexamethasone (IberDd), relapsed/refractory multiple myeloma. Priority Review and Breakthrough Therapy Designation; NDA accepted 2026-02-17 on EXCALIBER-RRMM MRD-negativity data. The only dated company-specific binary inside the window.
• ~2026-09 (est.) — FDA action on the Camzyos (mavacamten) sNDA for adolescents aged 12 to <18 with symptomatic obstructive hypertrophic cardiomyopathy, supported by SCOUT-HCM (23 on mavacamten, 21 on placebo, 28 weeks). The exact day was not published in the PDUFA calendars reviewed for this note.
• Beyond the window: ~2026-10-29 (est.) — Q3 2026 results. First independent check on whether the raised $49.000–50.000B FY sales range and $6.75–7.00 adjusted EPS range hold.

Elapsed catalysts

• No fixed date — further AstraZeneca reporting. After the 2026-08-05 Reuters denial, the burden sits on a confirmed filing or company statement; recurring press speculation without one is not a new datapoint. (passed 4d ago)

What Would Change Our Mind

The whole re-rating stands on one reporting date. Three things would break it.

First, the regulatory print: if 2026-08-17 passes with a complete response letter, a delay or a narrowed label, the near-term pipeline leg disappears and the discussion reverts to Eliquis and Opdivo exclusivity arithmetic.

Second, the structure. A daily close below $61 — roughly 5.7% under the 2026-08-07 close of $64.72 — would unwind the advance built after the 2026-07-30 guidance raise and indicate the print was faded rather than accumulated. A weekly close below $58 puts price under the lowest fresh sell-side anchor on the tape (Cantor, $59, 2026-07-31) and ends the re-rating read outright.

Third, the numbers themselves. FY2026 sales guidance walked back toward the prior $46.000–47.500B range at the Q3 print, or the Eliquis FY2026 growth outlook trimmed from 20–25%, would mark the raise as a first-half timing effect. Separately, if price-target revisions stop arriving and merger headlines keep recycling without a filing, the theme reads SATURATED and the marginal bid thins.

Correlation Notes

• AZN is the direct pair. The 2026-08-02 report and the 2026-08-05 denial make AstraZeneca headlines a two-way driver here; AstraZeneca appeared in the 2026-08-03 pre-market decliners list while BMY surged, which is the standard acquirer/target split on a merger report.
• Sector beta. Large-cap pharma (XLV, XPH constituents — MRK, PFE, ABBV) usually gains relative strength when risk appetite fades. On 2026-08-03 the tape did the opposite — oil down 6%, Nasdaq 100 rallying on Iran talks — and BMY still surged, so that session's move was idiosyncratic to the merger report.
• Policy factor common to the group. US drug-pricing and tariff headlines move the whole cohort together. Eliquis sits in the first CMS negotiation cohort with negotiated prices effective 2026-01-01, which makes BMY a higher-sensitivity name inside that headline class.
• Replimune (REPL) cross-read. RP1 secured FDA approval on 2026-08-07 after two prior rejections and a positive advisory-committee vote on 2026-07-31; the regimen was studied in combination with nivolumab in anti-PD-1-failed melanoma, so it reads as second-order support for the Opdivo franchise rather than competition against it.